Rajesh Bhola, MD
Cardiovascular Disease · Bellingham, WANPI 1356365001
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (32.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 59.1% of the total. Reporting peaked in 2022 at $8,273 and has fallen 79.8% since, to $1,667 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $130.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14K
- Welch Allyn$3K
- Medtronic$2K
- Edwards Lifesciences$1K
- Boston Scientific$1K
- Pfizer$372
- plus $2K from 25 others
What the payments were for
- Consulting fees$1,2905%
- Speaking & faculty fees$7,51932%
- Travel & lodging$7,82033%
- Food & beverage$4,00017%
- Other$3,13913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 34 | $14,054 |
| Welch Allyn | 1 | $3,139 |
| Medtronic(2 entities) | 22 | $1,775 |
| Edwards Lifesciences | 3 | $1,395 |
| Boston Scientific | 11 | $1,062 |
| Pfizer | 23 | $372 |
| Novartis | 18 | $275 |
| Johnson & Johnson | 12 | $250 |
| Merck | 10 | $189 |
| Heartflow, Inc. | 5 | $178 |
| Shockwave Medical, Inc | 1 | $163 |
| Impulse Dynamics (USA) Inc. | 5 | $128 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $83 |
| Medicomp Inc | 4 | $75 |
| Organogenesis Inc. | 1 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Boehringer Ingelheim | 2 | $47 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Terumo Medical Corporation | 1 | $45 |
| AstraZeneca | 3 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Bayer | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $17 |
| Itamar Medical Inc | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,769 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 269 | $326,813 |
| XareltoRivaroxaban | 177 | $194,761 |
| CamzyosMavacamten | 12 | $84,950 |
| EntrestoSacubitril/Valsartan | 34 | $40,475 |
| MultaqDronedarone Hcl | 13 | $22,663 |
| FarxigaDapagliflozin Propanediol | 30 | $20,484 |
| JardianceEmpagliflozin | 11 | $11,724 |
| Repatha SureclickEvolocumab | 12 | $5,991 |
| Metoprolol Succinate | 280 | $3,865 |
| Atorvastatin Calcium | 221 | $3,456 |
| Amiodarone Hcl | 63 | $2,394 |
| Losartan Potassium | 126 | $1,435 |
| Amlodipine Besylate | 132 | $1,346 |
| Potassium Chloride | 68 | $1,100 |
| Lisinopril | 140 | $1,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $372 | $326,813269 claims |
| Johnson & JohnsonXarelto | $250 | $194,761177 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $62 | $84,95012 claims |
| NovartisEntresto | $275 | $40,47534 claims |
| Sanofi-aventis U.S. LLCMultaq | $63 | $22,66313 claims |
| AstraZenecaFarxiga | $42 | $20,48430 claims |
| Boehringer IngelheimJardiance | $47 | $11,72411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 cardiovascular disease providers in Washington.
Other cardiovascular disease in Bellingham
- Kevin SteelBellingham$12K
- Paul ConnorBellingham$9K
- Robert BersinBellevue$657K
- Mariko HarperSeattle$246K
- Gary OppenheimSeattle$153K
- Kelley BranchSeattle$103K
- Munish Kumar KannabhiranRichland$85K
- Erik WissnerSeattle$67K
- Younghoon KwonSeattle$66K
- Thomas AmidonBellevue$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.